Related Experiment Video
Updated: Apr 5, 2026
06:00
Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
Published on: March 17, 2023
957
[Study on sustained release preparations of Epimedium component].
Summary
Researchers developed a sustained-release Epimedium tablet formulation using hydroxypropyl methylcellulose (HPMC) and colloidal silica. The optimized tablet demonstrated controlled drug release, successfully modeled by primary release kinetics.
Area of Science:
- Pharmacology
- Materials Science
Background:
- Epimedium component requires sustained-release formulations for improved therapeutic efficacy.
- Enhancing the liquidity of Epimedium component is crucial for tablet manufacturing.
Purpose of the Study:
- To develop and optimize a sustained-release tablet formulation for an Epimedium component.
- To establish in vitro release evaluation equations for the sustained-release tablets.
Main Methods:
- Colloidal silica and spray drying were used to improve component liquidity.
- Sustained-release tablets were prepared by dry compression using specific ratios of Epimedium component, HPMC K(4M), HPMC K(15M), MCC, PEG6000, and magnesium stearate.
- In vitro dissolution testing was performed to evaluate the release characteristics.
Main Results:
- The optimized formulation released up to 80% of the drug in 8 hours.
- Zero-order, primary, and Higuchi equations simulated in vitro release, with correlation coefficients (r) > 0.96.
- The primary equation best described the release profile (r = 0.9950).
Conclusions:
- A simple and reliable method for preparing Epimedium sustained-release tablets was established.
- The developed formulation ensures controlled drug release, suitable for therapeutic applications.
- The study provides guidance for the industrial production of Epimedium sustained-release preparations.
More Related Videos
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Overview
175
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
175
01:26Oral Drug Delivery Systems: Continuous-Release Systems
222
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
222
01:28Adrenergic Agonists: Mixed-Action Agents
1.7K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.7K
01:20Modified-Release Drug Delivery Systems: Influencing Factors
141
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
141
01:27Drug Delivery Systems: Different Types
258
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
258
01:11Oral Drug Delivery Systems: Delayed-Release Systems
152
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
152